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Introduction
 Bone mass and function are maintained through 
remodeling, which involves bone resorption by 
osteoclasts and bone formation by osteoblasts1. 
When the balance of bone remodeling shifts 
towards bone resorption over bone formation, bone 
destructive diseases can occur such as osteoporo-
sis2, rheumatoid arthritis3, periodontal disease4 
and bone metastases of malignant neoplasms5. 
On the other hand, when an imbalance exists 
involving excessive bone formation, osteosclerotic 
diseases such as osteopetrosis6 can occur.
 Osteoclasts originate from monocyte/mac-
rophage hematopoietic cells, and osteoclast pre-
cursor cells differentiate into osteoclasts on the 
bone surface.  The differentiation and functional 
expression of osteoclasts are closely regulated by 
osteoblasts7, which express the factors necessary 
for osteoclast differentiation.  Those factors 
 Received 8/2/07 ; revised 12/21/07 ; accepted 12/28/07.
 Grant support : Osaka Dental University Joint Research Funds 
(A06-08), Grant-in-Aid (17791569) for Young Scientists (B) from 
MEXT. and MEXT. HAITEKU, 2007–2011.
 Requests for reprints : Yumiko Ogawa, Graduate School of 
Dentistry (Department of Oral and Maxillofacial Surgery), Osaka 
Dental University, 8–1, Kuzuha Hanazono-cho Hirakata-city Osa-
ka, 573–1121, Japan, Phone : +81–72–864–3080, Fax : +81–72–864– 
3180, E-mail : o-yumi@stu.osaka-dent.ac.jp
Oral Science International, May 2008, p.15-23
Copyright © 2008, Japanese Stomatology Society. All Rights Reserved.
The Effect of Methyl-β-cyclodextrin on  
the Differentiation of RAW264 Cells  
into Osteoclasts
Yumiko Ogawa1, Seiji Goda2 and Shosuke Morita3
1Graduate School of Dentistry (Department of Oral and Maxillofacial Surgery),  
Osaka Dental University 
2Biochemistry, Osaka Dental University 
3First Department of Oral and Maxillofacial Surgery,  
Osaka Dental University
Abstract : Bone is continuously remodeled by bone resorption and formation and, accordingly, bone 
metabolism is tightly regulated to maintain homeostasis. Deviation from the normal conditions of 
bone resorption can result in bone diseases.  Lipid rafts are specialized plasma membrane microdo-
mains that are enriched with glycosphingolipids, sphingomyelin and cholesterol. Lipid rafts are 
important for the transport of select membranes and relay stations involved in intracellular signal-
ing.
 To investigate the role of lipid rafts in RAW264 cells signaling, lipid rafts were disrupted by de-
pleting cholesterol through the introduction of methyl-β-cyclodextrin (MβCD).  We found that 
sRANKL-induced differentiation into osteoclasts was markedly inhibited by MβCD in a dose-de-
pendent manner.  MβCD enhanced the sRANKL-induced phosphorylation of ERK1/2 MAP kinase.  
In contrast, MβCD blocked the phosphorylation of IκB.  These ﬁndings suggest that cholesterol 
might play a crucial role in the regulation of the sRANKL-mediated signaling pathway and in os-
teoclast differentiation of RAW264 cells, thereby reﬂecting its importance in the formation of plas-
ma membrane lipid rafts.
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include macrophage-colony stimulating factor 
(M-CSF) and the receptor activator of nuclear fac-
tor-κB ligand (RANKL), a type II membrane and 
osteoclast differentiation factor belonging to the 
TNF ligand family7.  Osteoclast precursor cells 
also express c-Fms and RANK (M-CSF and 
RANKL receptors, respectively)8.  Osteoclast pre-
cursor cells recognize RANKL through cellular 
contact with osteoblasts and differentiate into 
mononuclear osteoclasts in the presence of M-CSF, 
and then form multinucleated giant cells via cell 
fusion9.  Because disruptions in the regulation of 
bone remodeling can induce various bone metabo-
lism disorders, clarifying our understanding of the 
formation and functional regulation of osteoclasts 
is very important.
 Lipid rafts are special microdomains that are 
not dissolved by nonionic surface active agents. 
These are microdomains where sphingolipids and 
cholesterol are densely aggregated.  They exist in 
the lipid bilayer of the plasma membrane.  Lipid 
rafts are involved in membrane-based protein 
transfer during cell adhesion or activation10.  Lipid 
rafts are also closely involved in apoptosis and 
activation of all immunocompetent cells and play 
a role in clinical events, such as the onset of auto-
immune diseases ; allergic immune abnormalities ; 
and the elimination of bacteria, viruses, trans-
planted organs or cancer11–13.  Methyl-β-cyclodex-
trin (MβCD) is a compound that speciﬁcally binds 
to cholesterol and destroys lipid rafts.  Studies 
have documented that treating cells with MβCD 
disrupts signal transduction through lipid 
rafts 14,15.
 Lipid rafts contain proteins that are subject to 
lipid modiﬁcation.  These include phosphati-
dylinositol, GPI-bound protein, Src kinase, and 
the linker of activated T cell (LAT).  Furthermore, 
because these molecules are involved in signal 
transduction, the plasma membrane domain of 
lymphocytes may be involved in the control of sig-
nal transduction systems having the plasma mem-
brane as the initial active site16.  The aggregation 
of plasma membrane receptors is also essential for 
activation of intracellular signal transduction.  In 
RAW264 cells (a murine monocyte cell line), 
RANK is found in lipid rafts, and in the presence 
of soluble RANKL (sRANKL), lipid rafts aggregate 
to form a basis for signal transduction17.  However, 
the relationship between osteoclast differentiation 
and lipid rafts has not been clariﬁed.  We investi-
gated the effects of MβCD on sRANKL-induced 
osteoclast differentiation in RAW264 cells.
Materials and Methods
1. Cell Culture
 RAW264 cells were obtained from Riken (Ibar-
agi, Japan).  Cells were maintained in minimal 
essential medium alpha modiﬁcation (α-MEM) 
(Wako Pure Chemicals, Osaka, Japan) containing 
10% fetal bovine serum (FBS) (Equitech-Bio Inc., 
TX, USA), 100 unit/ml penicillin G sodium, 100 
μg/ml streptomycin, and 292 μg/ml L-glutamine 
(Invitrogen Co., CA, USA).  RAW264 cells were 
incubated at 37℃ under 5% CO2.  Trypsin-EDTA 
(0.05% trypsin, 0.53 mM EDTA-4Na) (Invitrogen 
Co., CA, USA) was used to detach cells.
2. Reagents and Antibodies
 MβCD was purchased from Sigma-Aldrich (MO, 
USA), recombinant human sRANKL was obtained 
from Pepro Tech EC (London, UK), and phosphate 
buffer solution [PBS: Dulbecco's PBS(－)] was pro-
cured from Nissui (Tokyo, Japan).  Anti-β-Actin 
antibodies were purchased from Sigma-Aldrich 
(MO, USA).  The following items were purchased 
from Cell Signaling (MA, USA) : anti-phospho-
ERK1/2 MAP kinase, anti-ERK1/2 MAP kinase, 
anti-phospho-p38 MAP kinase, and anti-p38 MAP 
kinase, and anti-phospho-IκB antibodies.  
3. Measurement of Cell Proliferation
 RAW264 cells (1.0× 106) were placed in each 
well of a 6-well plate and incubated for 24 hours. 
After washing the cells with PBS(－), they were 
incubated for 24 hours in a culture solution con-
taining 0, 0.1, 0.5, or 1.0 mM of MβCD, respec-
tively.  The incubated cells were detached, recov-
ered, and then counted using a hemocytometer 
under a light microscope.  Cell counts indicate the 
average of 3 wells.
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4. TRAP Staining
 For tartrate-resistant acid phosphatase (TRAP) 
staining, RAW264 cells (2.0× 103) were placed in 
each well of a 24-well plate and incubated for 24 
hours.  After washing the cells with PBS(－), the 
cells were incubated for 4 days in a culture 
medium containing 50 ng/ml sRANKL and 0, 0.1, 
0.5, or 1.0 mM of MβCD, respectively.  TRAP buf-
fer solution was prepared by mixing 0.1 M of 
sodium acetate (Wako Pure Chemicals, Osaka, 
Japan) and 50 mM of tartaric acid (Wako Pure 
Chemicals, Osaka, Japan) in a 1 :1 ratio, and 
adjusted to pH 5.  TRAP staining solution was 
prepared by mixing 50 ml of TRAP buffer solution, 
5 mg of naphthol AS-MX phosphate (Sigma-
Aldrich, MO, USA), 0.5 ml of N,N-dimethylforma-
mide (Wako Pure Chemicals, Osaka, Japan), and 
25 mg of Fast Red Violet LB salt (Sigma-Aldrich, 
MO, USA).  Cells were ﬁxed in 4% paraformalde-
hyde phosphate buffer (Wako Pure Chemicals, 
Osaka, Japan) followed by exposure to an acetone 
and ethanol mixture (1 :1) (Wako Pure Chemicals, 
Osaka, Japan).  The ﬁxed cells were treated with 
the TRAP staining solution for 20 minutes, 
washed with water, and observed under a light 
microscope.  Osteoclasts were deﬁned as multinu-
cleated cells having at least three TRAP-positive 
nuclei.  The number of osteoclasts in each well 
was counted, and cell counts reﬂected the average 
number of osteoclasts for 3 wells.
5. Western Blotting
 RAW264 cells (1.0× 106) were placed in each 
well of a 24-well plate and incubated for 24 hours. 
After washing the cells with PBS(－), the cells 
were treated with 1.0 mM MβCD for 30 minutes 
and then 50 ng/ml sRANKL for 15 minutes.  We 
then added cell lysis buffer solution [0.0645 M Tris 
HCl (pH 6.8), 2% sodium dodecyl sulfate (SDS), 
10% glycerol, 5% 2-mercaptoethanol (2-ME), and 
bromophenol blue (BPB)], and cells were detached 
from the plate and subjected to sonication using a 
Branson digital soniﬁer 450 (Branson Ultrasonics, 
Danbury, CT, USA).  Cells were then boiled at 
99℃ for 3 minutes to prepare them for electropho-
resis.  Equal amounts of each sample were then 
subjected to 10% SDS/PAGE and transferred to 
Immbilon-P PVDF membranes (Millipore, TX, 
USA).  Anti-phospho-ERK1/2 MAP kinase, anti-
ERK1/2 MAP kinase, anti-phospho-p38 MAP 
kinase, anti-p38 MAP kinase, anti-phospho-IκB, 
and anti-β-Actin antibodies were used as primary 
antibodies, with either horseradish peroxidase 
(HRP)-labeled anti-mouse or anti-rabbit antibod-
ies being used as secondary antibodies (Amersham 
Biosciences Co., NJ, USA).  The ECL Detection 
System was purchased from Pierce (IL, USA). 
Anti-phospho-ERK1/2 MAP kinase, Anti-phospho-
p38 MAP kinase or anti-phospho-IκB antibodies 
were used as primary antibodies.  HRP-labeled 
anti-mouse antibodies were used as secondary 
antibodies.  After the incubation with the antibod-
ies, phosphorylated proteins were detected by 
SuperSignal West Pico Chemiluminescent Sub-
strate (Pierce, IL, USA) and VersaDoc 500 (ECL 
system, BioRad, Hercules, CA, USA).  The same 
membrane was treated with WB Stripping Solu-
tion Strong (Nacalai, Kyoto, Japan) to eliminate 
the above-mentioned primary and secondary anti-
bodies.  This was followed by treatment with anti-
ERK1/2 MAP kinase, anti-p38 MAP kinase or 
anti-β-Actin antibodies (primary antibodies), and 
HRP-labeled anti-mouse or anti-rabbit secondary 
antibodies for evaluating protein expression.
Results
1.  Effect of MβCD on RAW264 Cell Prolifera-
tion
 We tested whether MβCD affect cell prolifera-
tion on RAW264 cells.  RAW264 cells were placed 
in wells and then incubated for 24 hours.  After 
washing the cells with PBS, the cells were incu-
bated for 24 hours in a culture medium containing 
0, 0.1, 0.5, or 1.0 mM of MβCD, respectively.  Mβ
CD did not affect proliferation in RAW264 cells 
(Fig. 1). 
2.  Effect of MβCD on sRANKL-Induced Dif-
ferentiation of RAW264 Cells into Osteo-
clasts
 Inoue et al. reported that lipid rafts regulate cell 
signaling, such as localization of CD2 and cytotox-
icity, which are induced by CD2 cross linking on 
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NK3.3 cells18.  We tested whether MβCD affects 
sRANKL-induced differentiation into osteoclasts 
on RAW264 cells.  When RAW264 cells were stim-
ulated with sRANKL (50 ng/ml), numerous TRAP-
positive multinucleated osteoclasts were formed 
(Fig. 2B).  We examined the respective effects of 
0.1, 0.5, or 1.0 mM MβCD on sRANKL-induced 
differentiation of RAW264 cells into osteoclasts. 
Differentiation of RAW264 cells into osteoclasts 
was signiﬁcantly suppressed by MβCD in a dose-
dependent manner (Figs. 2 and 3).  
3.  Effects of sRANKL on Phosphorylation of 
ERK1/2 MAP Kinase and p38 MAP Kinase
 Studies have shown that ERK1/2 and p38, 
which are MAP kinases, are involved in differenti-
ation of sRANKL-treated osteoclast precursor cells 
into osteoclasts19,20.  Chronologic changes in phos-
phorylation of ERK1/2 MAP kinase and p38 MAP 
kinase, due to sRANKL stimulation, were investi-
gated via Western blotting.  It was found that 
sRANKL enhanced the phosphorylation of ERK1/2 
MAP kinase (Thr202/204) and p38 MAP kinase 
(Thr180/182) with a peak of 15 minutes after 
stimulation in RAW264 cells (Fig. 4).
4.  Effects of MβCD on Phosphorylation of 
ERK1/2 MAP Kinase and p38 MAP Kinase
 It has been reported that the phosphorylation of 
ERK1/2 MAP kinase was increased by treatment 
with p38 MAP kinase inhibitor, whereas MEK 
inhibitor increased the phosphorylation of p38 
MAP kinase21.  This implies a seesaw-like balance 
between ERK1/2 MAP kinase and p38 MAP 
kinase phosphorylation.  Osteoclastogenesis is 
regulated by a balance between ERK1/2 MAP 
kinase and p38 MAP kinase pathways.  The MEK/
ERK pathway negatively regulates osteoclasto-
genesis while the p38 MAP kinase pathway posi-
tively regulates it21.  Since MβCD inhibited 
sRANKL-induced differentiation of RAW264 cells 
into osteoclasts, the effects of MβCD on the phos-
phorylation of ERK1/2 MAP kinase and on p38 
MAP kinase were investigated using Western blot-
ting.  In RAW264 cells, MβCD enhanced the 
sRANKL-induced phosphorylation of ERK1/2 
MAP kinase in a dose-dependent manner (data 
not shown).  1.0 mM MβCD slice increased the 
phosphorylation of ERK1/2 MAP kinase (Fig. 5A). 
1.0 mM MβCD did not affect the phosphorylation 
of p38 MAP kinase compared with sRANKL-
induced phosphorylation (Fig. 5B).
Fig. 1 Effect of MβCD on RAW264 cell proliferation.
RAW264 cells (1.0× 106 per well) were cultured in a 6-well plate for 
24 hours.  After washing with PBS(－), the cells were cultured for 24 
hours in the presence of 0.1, 0.5, or 1.0 mM MβCD, respectively. 
Cells were detached and recovered, and the number of RAW264 cells 
was counted. The experiment was conducted three times. Cell 
counts reﬂect the average of the data from 3 wells.
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Fig. 3 MβCD decreases osteoclasts induced by sRANKL.
The number of TRAP-positive multinucleated cells containing three or 
more nuclei were scored. The experiment was conducted three times. 
Cell counts indicate the average of the data for 3 wells (＊ : p < 0.05 and 
＊＊ : p < 0.01).
Fig. 2 Effect of MβCD on sRANKL-induced differentiation of RAW264 cells into osteoclasts.
RAW264 cells (2.0× 103 per well) were cultured in a 24-well plate for 24 hours. After washing with PBS(－), the result-
ing cells were cultured for 4 days with : no addition (A), 50 ng/ml sRANKL (B), 50 ng/ml sRANKL and 0.1 mM MβCD 
(C), 50 ng/ml sRANKL and 0.5 mM MβCD, or (D), 50 ng/ml sRANKL and 1.0 mM MβCD (E), respectively.  Cells were 
then subjected to TRAP assays. Numerous TRAP-positive multinucleated osteoclasts were formed.  Arrows indicate 
TRAP-positive multinucleated cells (TRAP staining,×100). 
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5. Effect of MβCD on Phosphorylation of IκB 
 RANKL signaling pathways in osteoclasts rely 
on the activation of IκB, a crucial process for the 
differentiation of osteoclasts and for bone homeo-
stasis22,23.  Since MβCD affect the phosphorylation 
of ERK1/2 MAP kinase, we investigated the effect 
of MβCD on the sRANKL-induced phosphoryla-
tion of IκB.  MβCD partially blocked the phos-
phorylation of IκB that had been induced by 
sRANKL in RAW264 cells (Fig. 5C).  
Discussion
 Bone is the core of the skeletal system and is a 
place for blood cells to multiply and differentiate. 
Bone also functions as a storage shed for minerals 
which regulates blood calcium and phosphate lev-
els.  In bone, old tissue is constantly being 
replaced by new tissue and the maintenance of 
bone homeostasis requires a precise balance 
between bone formation by osteoblasts and bone 
resorption by osteoclasts1.  When this balance is 
disturbed, bone metabolism disorders are induced. 
Osteoclasts control bone resorption by releasing 
H+ via type II carbonic anhydrase, secreting pro-
teases such as cathepsin K and matrix metallopro-
teinases (MMPs), and secreting TRAP, which we 
used as a osteoclast formation marker.  
 The lipid bilayer of the plasma membrane is not 
uniform and has characteristic microdomains con-
sisting of several types of lipids.  Because these 
microdomains contain G-protein coupled receptors 
for many physiologically active substances, they 
are thought to play a central role in the informa-
tion exchange of the plasma membrane24.  Lipid 
rafts are rich in sphingolipids, cholesterol, and 
glycolipids and are believed to be dynamic and 
ﬂuid microdomains where synthesis and destruc-
tion are repeated.  They play important roles in 
intracellular transportation and signaling.  In 
human embryonic kidney cells, RANK, TRAF2 
and TRAF6 exist in lipid rafts and are involved in 
RANKL signal transduction25.
 In this study, we investigated the effect of Mβ
CD on sRANKL-induced differentiation of 
RAW264 cells into osteoclasts.  Since 1.0 mM Mβ
CD had no effect on the proliferation of RAW264 
Fig. 4 Effects of sRANKL on phosphorylation of ERK1/2 MAP kinases and p38 MAP  
kinases.
RAW264 cells (1.0× 106 per well) were cultured in a 24-well plate for 24 hours. Cells 
were treated with sRANKL (50 ng/ml) for 0, 5, 15, or 30 minutes, respectively.  Total cell 
lysates were prepared, as described in the Materials and Methods section above, and 
were subjected to Western blotting. After blocking, total cell lysates were separated on 
SDS-PAGE and blotted with anti-phospho-ERK1/2 MAP kinase and anti-phospho-p38 
MAP kinase antibodies and visualized with a SuperSignal West Pico Chemiluminescent 
Substrate. The same membranes were stripped and reprobed with anti-ERK1/2 MAP ki-
nases and with anti-p38 MAP kinases antibodies.
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cells, we tested the effect of MβCD on sRANKL-
induced cell differentiation into osteoclasts.  Mβ
CD suppressed the sRANKL-induced differentia-
tion of RAW264 cells into osteoclasts in a dose-
dependent manner.  These ﬁndings suggest that 
lipid rafts are more closely involved with the dif-
ferentiation of RAW264 cells into osteoclasts than 
with the proliferation of RAW264 cells.  A study 
using T cells found that MβCD facilitate the phos-
phorylation of ERK1/2 MAP kinase15.  MAP 
kinases, such as p38 and ERK1/2, are known to be 
involved in the differentiation of osteoclasts. 
sRANKL enhanced the phosphorylation of p38 
MAP kinase and ERK1/2 MAP kinase19,20. 
PD169316 and SB203580, both p38 MAP kinase 
inhibitors, increased the phosphorylation of 
ERK1/2 MAP kinase and suppressed osteoclast 
differentiation21.  We examined whether MβCD 
affect the phosphorylation of ERK1/2 MAP kinase 
and p38 MAP kinase.  MβCD slice facilitated the 
phosphorylation of ERK1/2 MAP kinase.  MβCD 
did not affect the phosphorylation of p38 MAP 
kinase.  RANKL signaling pathways in osteoclasts 
rely on the activation of IκB, a process that is crit-
ical for the differentiation of osteoclasts and for 
bone homeostasis22,23.  MβCD blocked the phos-
phorylation of IκB.  These ﬁndings suggest that 
IκB might be involved in the MβCD-dependent 
Fig. 5 Effects of MβCD on phosphorylation of ERK1/2 MAP kinase, p38 MAP kinase, 
and IκB.
RAW264 cells (1.0× 106 per well) were cultured in a 24-well plate for 24 hours, treated 
with either 0 or 1.0 mM MβCD, respectively for 30 minutes and then treated with 50 ng/
ml sRANKL for 15 minutes. Cell lysates were separated on SDS-PAGE and blotted with 
anti-phospho-ERK1/2 MAP kinase and with anti-phospho-p38 MAP kinase and anti-phos-
pho-IκB antibodies. They were then visualized with a SuperSignal West Pico Chemilumi-
nescent Substrate. The same membranes were stripped and reprobed with anti-ERK1/2 
MAP kinases, anti-p38 MAP kinases, and anti-β-Actin antibodies.
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suppression of sRANKL induced differentiation 
into osteoclast.
 In the future, it will be necessary to more thor-
oughly analyze the relationship between lipid 
rafts and the differentiation of osteoclast precur-
sor cells into osteoclasts, including other proteins 
that are important for differentiation, prolifera-
tion and apoptosis.  If it becomes possible to con-
trol lipid raft function, we would then be able to (1) 
selectively suppress osteoclast differentiation and 
treat various bone metabolism disorders caused 
by increased bone resorption, and (2) facilitate the 
development of new treatment protocols.
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